Study of High Efficient Killing Cell Therapy for Advanced NSCLC (HEART)

Shanghai Jiao Tong University

Status and phase

Enrolling

Phase 1

Conditions

Non Small Cell Lung Cancer

Treatments

Biological: HEKT cell

Study type

Interventional

Funder types

Other

Identifiers

NCT03193567

RTS-005

Details and patient eligibility

About

The purpose of this study to preliminarily evaluate the safety and efficacy of High Efficient Killing Cell Therapy for refractory and advanced non-small cell lung cancer

Full description

Patients with pathological confirmed non-small cell lung cancer with no standard treatment are enrolled. The patients fails in previous at least 2 lines of chemotherapy and 1 line of targeted therapy where applicable. This is a prospective exploratory trial.

Enrollment

15 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Male or female patients' age from 18 years to 70 years.
Patients who have a life expectancy of at least 3 months.
pathologically confirmed non-small cell lung cancer.
failed in previous standard chemotherapy and targeted therapy.
Karnofsky performance status 0-1.
adequate organ functions.

Exclusion criteria

Pregnant and lactating women.
Patients with T cell lymphoma, syphilis, AIDS or combination
Patients with highly allergic or have a history of severe allergies
Patients with severe hepatic or renal dysfunction
Patients with severe autoimmune disease or who is being treated with immunosuppressive agents
Patients with severe infection not controlled or High fever
Patients with organ transplantation or waiting for organ transplantation.
Patients with brain metastasis
Patients with severe coagulopathy (e.g. hemophilia)
Patients without adequate ability to understand, sign informed consents and take part in the clinical research voluntarily.